If you liked this article you might like

Invest in Allergan on Weakness, Analysts Say
Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses
Could AbbVie's Buyout of Shire Make It a New Dividend Aristocrat?
European Markets Are Spooked by Ukraine and Gaza, but AbbVie Gets Shire Deal